Bioven is a wholly owned Malaysian biotechnology and healthcare company, with offices in the UK and Malaysia, that harnesses the resources of life sciences to identify, develop and commercialise effective cancer therapeutics in lung, prostrate and breast cancers. Established in 2002, our primary focus are in the area of Oncology and Therapeutic Cancer Vaccines. Fusing cutting edge technologies and strategic market-based solutions, we are set to launch ourselves into the global pharmaceuticals market by introducing ‘first-of-a-kind’ life-saving health care products. With our in-depth international experience in global vaccine development and commercialisation, coupled with our partnership with Cuba, a country that is globally acknowledged by world experts for its advanced science, Bioven is currently one of a small group of global companies in the world that focuses on late stage Lung Cancer Vaccine development. Our EGF vaccine is a non-toxic immunotherapy that can extend, in many patients, overall survival in advanced NSCLC. Bringing hope to lung cancer sufferers by giving them a better quality of life and extended time with their loved ones. Tan Sri Abu Bakar Chairman Johan Indot Executive Director Steve Drew Group Chief Executive Officer Erik D'Hondt Chief Scientific Officer and Head of Regulatory Affairs Professor Andrew Porter Non Executive Director Dr Martin Drysdale Non Executive Director David Baynes Non Executive Director   Our website is currently under construction.    For more information, please email us: info@bioven.com.my                  Copyright © 2009 Bioven.